论文部分内容阅读
目的 探讨白细胞介素-18(IL-18)在重型病毒性肝炎(重肝)早期中的作用以及N-乙酰半胱氨酸(NAC)治疗重肝对IL-18水平的影响,为重肝提供新的治疗方法。方法 采用夹心酶联免疫吸咐法(ELISA)分析65例重肝患者血清IL-18、γ-干扰素(γ-IFN)、一氧化氮(NO)和可溶性细胞间粘附分子-1(SICAM-1)的水平表达,以及动态变化;通过NAC治疗(29)例与综合治疗(36例)的自身治疗前、后及治疗后两组中疗效的对比,观察TL-18、γ-IFN、NO和SICAM-1水平表达的变化及相关性。结果重肝患者血清上述四项指标水平较正常对照组有非常显著性差异。NAC治疗组血清上述四项指标自身治疗前、后比较有非常显著性意义。对NAC治疗组四项指标与SB、PA相关性分析发现,治疗后四项指标与SB改变呈显著正相关,与PA改变呈显著负相关。结论 IL-18等细胞物质与重肝具有相关性。NAC可降低上述物质的水平,可用于治疗重肝。
Objective To investigate the role of interleukin-18 (IL-18) in the early stage of severe viral hepatitis (severe liver) and the effects of N-acetylcysteine (NAC) on the level of IL-18 in severe liver. Provide new treatments. Methods Serum levels of IL-18, γ-IFN, NO and SICAM in 65 patients with severe hepatitis were analyzed by sandwich enzyme-linked immunosorbent assay (ELISA) -1), and the dynamic changes of TL-18, γ-IFN, TNF-α and IFN-γ in patients with NAC treatment (29 cases) and comprehensive treatment (36 cases) before and after treatment and after treatment. Changes of NO and SICAM-1 levels and their correlations. Results The serum levels of the above four indicators of patients with severe hepatitis than the normal control group has a very significant difference. Serum NAC treatment group above four indicators of self-treatment before and after the comparison has a very significant significance. Four indicators of NAC treatment group and SB, PA correlation analysis found that after treatment four indicators and SB changes was significantly positive correlation, and PA changes was significantly negatively correlated. Conclusion IL-18 and other cellular substances are associated with severe liver. NAC can reduce the level of these substances can be used to treat severe liver.